contravir pharmaceut inc ctrv hold balanc get tight step hold remov price
mynd analyt inc mynd hold watch balanc result believ prudent move hold rate
buy rate analyst jason kolbert full summari
athersi inc buy pt travers data trough lower price see
catalyst year ahead analyst jason kolbert full summari
anavex life scienc corpor buy pt lower price definit proof concept
poc take time money analyst jason kolbert full summari
cytori inc cytx buy pt right valuat cytori binari event ahead lower
price analyst jason kolbert full summari
interpac diagnost group inc idxg buy pt includ risk cut model result
price target fall analyst jason kolbert full summari
isoray inc isr buy pt remov technolog platform valu isoray commerci compani
take price analyst jason kolbert full summari
soleno inc slno buy pt lower price travers data trough
 buy pt recent pullback valu share maintain buy
 buy pt incom ceo brian niccol check box turnaround
dineequ inc buy pt stabil tri expect tax save support
maintain buy pt analyst stephen anderson full summari
corpor event call maxim salesperson inform
landec corpor cover vendetti ndr boston cfo greg skinner tue feb
dineequ inc cover ndr san francisco ceo stephen joyc interim cfo gregori
kalvin execut director ir ken dipte mon feb
cover ndr boston cfo golder wed jun
keyw hold corp keyw cover kinstling ndr san francisco ceo weber wed thu feb
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corp cover kinstling ndr boston cfo ranjan kalia wed
payment data system inc pyd host kinstling ndr nyc ceo loui hoch cfo tom jewel
stabil tri expect tax
save support brand maintain buy pt
maintain buy rate price target dineequ ahead
releas decemb result tuesday februari
reduc ep estim account
increas market spend lower franchis segment profit though
revenu estim mostli unchang
lower ep estim though expect gain
lower tax rate invest support applebe ihop brand
maintain din dividend potenti buy back share
expect provid detail guidanc long-term
strategi compani investor day confer schedul
held new york wednesday februari
reduc ep estim account lower
franchis segment profit increas market spend though revenu
estim mostli unchang estim million contribut
dineequ corpor applebe ad fund lower din near-term
profit payment toward applebe sales-build effort
estim addit reduc royalti well addit
market spend sg line nevertheless believ increas market
spend success model improv one-year two-
year stack comp applebe ihop
lower ep estim though expect gain
lower tax rate invest support applebe ihop brand
well maintain din dividend yield accord
model reduct long-term tax rate assumpt add
annual ep believ could addit ep upsid base
outlook ancillari effort particularli acceler remodel ihop
eventu applebe franchise
like howev probabl manag reinvest save tax
reform support brand model addit
believ invest manifest stabl same-restaur sale
model revis comp applebe
unchang ihop detail sales-driv initi concept
novemb compani report new ceo stephen joyc like provid
detail guidanc long-term strategi compani investor day
confer schedul held new york wednesday februari
moreov expect maintain gener dividend yield
believ improv free cash flow leav room modest dividend
increas per model model also assum resum share buyback
model resumpt buyback would add increment ep
share recent low believ valuat remain compel
seek turnaround opportun gener dividend use
base valuat year equal weight forward price-to-earnings multipl base
multipl unchang ep estim yield
price target forward ev/ebitda multipl base multipl
yield price target sum-of-part yield price target
methodolog base unchang valuat multipl target arriv
click full note
recent pullback valu share
maintain buy pt
maintain buy rate price target cheesecak factori
ahead releas decemb result wednesday
lower ep estim believ post-
howev ep estim unchang model
comp benign food cost buyback
model reduct corpor tax rate updat model
lower ep estim vs guidanc
believ post-christma weather-rel slowdown like kept full-quart
comp slightli neg reduc comp
believ much-colder-than-usu post-christma week like kept traffic count
depress believ cold weather also hurt sale januari reduc
march traffic quarter-to-d hand contend cake
result help continu strength california texa florida
togeth compris cake restaur base accord knapp-track
recent comp trend settl posit pace market
moreov think strong end movi season receipt y/
even year overal like prevent
comp declin view box offic receipt potenti factor sale
compani highest exposur adjac movi theater among nation casual
dine concept locat within develop movi
ep estim unchang vs initi guidanc
model comp benign food cost buyback believ
pois gain solid gain dispos incom increas consum
confid post-tax reform mind rais full-year comp estim
part believ sever top-lin lever
dispos includ off-premis sale saturday brunch expect
contribut comp also said would test online/mobil order
though expect much catalyst earliest
regard food cost estim food cost inflat
current guidanc driven stable-to-slightly-low dairi grain protein
cost allow modest produc inflat rel initi guidanc
estim moder food cost outlook add much
ep also estim increment buyback add much
model direct benefit lower tax rate howev
rule potenti tax-rel ep upsid thu estim
reduct combin corpor tax rate increas annual ep
els equal
valuat becom attract recent pullback unchang
price target base sum-of-part methodolog correspond
forward price-to-earnings compani five-year averag well
base valuat year new price target correspond forward ev/
ebitda ratio compani five-year averag ratio
peak cyclic ratio also contend recent pullback
share compani dividend becom attract yield nearli
click full note
incom ceo brian niccol check box
maintain buy rate price target chipotl mexican grill
follow yesterday news brian niccol current serv
bell ceo would assum role cmg new ceo
view mr niccol check box regard brand leadership
menu innov technolog intern franchis develop
lower march ep estim accur
account one-tim expens post-tax-reform bonus though
leav ep estim unchang
despit recent sale volatil still argu pullback share
provid opportun investor particip compani recoveri
technolog
view mr niccol check box regard brand leadership
experi mr niccol assum new ceo role board membership
march serv bell ceo sinc serv
variou market oper capabl parent compani
note sinc mr niccol join bell late initi
chief market innov offic comp posit past
quarter averag quarterli comp mr niccol behind mani
bell menu innov notabl dorito loco launch
nationwid launch breakfast bell also earli adopt digit
market mobil payment mr niccol test in-stor order
kiosk recent bell announc initi build new franchis
locat outsid year focus canada latin america india
develop believ four attribut need move
turnaround stori renew growth stori anticip potenti
chang new ceo could extend capit alloc polici includ
limit franchis non-u market cmg restaur locat
outsid initi regular dividend
lower march ep estim accur account
one-tim expens post-tax-reform bonus though leav
ep estim unchang rel prior model estim bonus
employe manag account addit one-tim
expens model assum midpoint rang expect
expens recur futur quarter
still argu pullback share provid opportun investor
particip compani recoveri still anticip return
robust strong sale earn growth next quarter believ
retreat commod cost restaurant-level effici gain reinforc margin
expans buyback provid increment ep upsid multipli
forward price-to-earnings target unchang ep estim arriv
price target round correspond forward ev/
ebitda ratio long-run averag garner prior
 coli outbreak cmg short float percentag total float
weight industri averag better-than-expect
result updat guidanc potenti trigger short-cov ralli
click full note
watch balanc result believ
prudent move hold rate buy rate
recent file compani cash
balanc sheet modest burn rate capit last
middl howev concern may take longer
compani build traction diagnost tele-psychiatr
market compani may need rais addit capit time
valuat depress market difficult result believ
step rate hold buy remov price target
note risk mynd analyt small capit healthcar
compani limit resourc high risk predict action
regulatori bodi clinic data outcom well abil
exchang exist paradigm medicin difficult mynd
consid aggress investor awar risk present suggest
investor review price invest risk section end
note addit check compani file comprehens
list risk present capit rais abil rais capit
favor term becom key risk mani micro-cap healthcar
model adjust revis downward outyear growth
rate assumpt across variou market segment
conclus mynd repres new treatment paradigm mental
diseas diagnos treat follow-on therapi progress
like take time drive adopt hope see rise revenu
quarter ahead catalyst higher valuat concern
pullback valuat make rais capit difficult creat
downward pressur cash balanc rise concern choos
downgrad share hold buy remov price target
telepsychiatry- arcadian includ suit servic includ telepsychiatri
teletherapi digit patient screen curbsid consult demand servic
schedul encount age group hour day day week
shortag psychiatrist therapist well limit access payor
network patient arcadian solv problem larg provid
 nr aetna aet nr alreadi board exposur doc
payor peer on-line adopt increas doctor want abl treat
patient better quicker peer tool recruit doctor payor network
payor want save cost ideal parti mynd
psychiatr electroencephalographi evalu registri peer report act
guid clinician report identifi class therapeut
patient like respond exampl ssri vs snri valu
mood stabil and/or stimul patient crisi need achiev respons
quickli vs standard care today take month even year almost
alway poly-pharmaci peer provid clue clinician road map
patient may like respond mynd analyt test competit price
setup number compani arrang eeg
technician go patient hous simplifi process manag
identifi six key market segment initi commerci strategi focu sale
va system contract physician direct access intern market
academia industri
click full note
balanc get tight step hold
review compani announc yesterday posit fda
agre pathway valid txl hbv drug review model
time assumpt see balanc sheet
last report quarter show cash estim compani
spend almost per quarter result believ compani need
rais capit soon consist intern model assumpt
feel prudent step rate hold buy base fact
compani like rais capit soon
note risk contravir small capit biotechnolog compani
limit resourc high risk predict action regulatori bodi
clinic data outcom difficult contravir consid
aggress investor awar risk present suggest investor
review price invest risk section end note
addit check compani file comprehens list
risk present capit rais abil rais capit favor
term becom key risk mani micro-cap biotechnolog compani
conclus fundament posit outlook txl chang howev
balanc sheet concern repres key risk contravir stori result
feel prudent downgrad share hold buy remov
price target financi concern resolv
fda agre manag note press releas yesterday
receiv final written minut meet fda januari
summar outcom meet feedback receiv highlight
meet includ
agreement abbrevi non-clin develop program
agreement clinic pharmacolog packag
agreement major element phase trial design treatment-nav
patient chronic hepat hbeag heag includ durat
treatment clinic endpoint compar
agreement number patient safeti databas need nda
summari save time money marketplac see txl
viabl altern gilead buy viread previous
discuss part hing door strategi mean could backbon
regimen hbv combin offer altern viread
correct and/or clarif detail section note yesterday
renal impair studi done old formul manag
yet shown new formul result
txl prodrug tvf tenofovir tdf anoth prodrug viread
new formul introduc due dsmb permiss dose
escal told work progress
lipid moieti allow better liver target drug
txl time fold manag remind us origin basi
in-vitro experi held clinic
click full note
remov technolog platform valu isoray
commerci compani take price
isoray execut busi plan believ compani
show sign progress said elimin
technolog valu previous includ valuat metric
compani transit true commerci compani lower
price target
growth revenu y/i beat estim
increas revenu result isoray new market sale
rep strategi implement last year result show
top line
guidanc manag expect revenu grow
compani close quarter cash balanc sheet
current burn rate runway longer revenu continu
build drive margin offset expens
use isoray focus revit
prostat brachytherapi market promot use surgic
applic includ gynecolog head neck brain cancer
sale consist combin exist base user new
physician come board
gammatil expect approv recurr brain
cancer recal isoray sign manufactur agreement gt
medic technolog privat incorpor gammatil
collagen tile devic place bed resect brain tumor isoray
complet final biocompat studi expect
reimburs clearanc
background hit tumor fast hard approv
solid tumor broader adopt key market penetr
energi shorter half-lif mean
could use situat potenti better efficaci isotop
manag see interest build treatment brain cancer meningioma
brain metastas glioblastoma lung cancer nsclc gynecolog cancer
prostat cancer head neck cancer liquid gliasit radiat
therapi use treat brain cancer
see opportun revenu grow sale rep detail start impact usag
also see opportun margin climb fix cost relat manufactur
leverag across greater number patient brain cancer alon repres
patient gbm plu brain cancer breast lung metastas
could see signific revenu outyear prostat brain
indic develop recal last decad pendulum swung away
use radiat seed modal extern beam radiat robot surgeri
biolog mani limit therapi better understood set
stage market share shift back toward seed
valuat use fcff discounted-ep sum-of-the-part model
discount rate deriv price target price target longer includ technolog
platform valu compani transit true commerci
click full note
includ risk cut model result
price target fall
increas therapeut rate cut model result
price target fall market condit difficult
believ conserv metric appropri
recal mid-novemb report revenu
sequenti y/i compani report net loss
end period cash also rais
exercis warrant octob share issu total
cash balanc sheet debt end
favor chang reimburs come see thyroid test
platform thygenx thyramir dual test higher predic valu
vs other space like rosetta genom growth
driver compani announc center medicar
medicaid servic approv reimburs increas
thygenx test make thyroid revenu increas could add
addit revenu increas revenu outyear
adopt continu build
conclus see thyroid platform driver signific
increas reimburs believ singl largest payer
countri see valu well stronger balanc sheet today
cash hand posit unlock valu sharehold
view yet factor product earli stage
launch respirdx launch reimburs barregen
thygenx thyramir thygenx next gener dna rna sequenc
oncogen panel appli indetermin fna provid highli specif
rule-in test posit predict valu predict whether patient
thyroid nodul cancer thygenx work synergist thyramir
base microrna design provid highli sensit rule-out test
accur categor mutat neg indetermin fna benign
malign interpac assay two test offer price one
uniqu advantag test avail market addit interpac
recent announc use tert telomeras biomark thygenx
assay even focus identifi earli progress patient
head head analysi thygenx thyramir togeth provid highest posit
predict valu vs veracyt afirma
pancragen barregen pancragen determin risk malign pancreat
cyst market approxim product market
purpos similar thyroid fna vast major surgeri pancreat
cyst benign diseas pancragen provid highli reliabl diagnost option
distinguish patient pancreat cyst low high
risk develop pancreat cancer barregen util pathfind tg platform
support pancragen barregen develop determin patient
barrett esophagu high risk progress esophag cancer
 adult gastroesophag reflux diseas
progress cancer market size
click full note
lower price travers data
increas therapeut rate cut model
across us europ indic result price target
fall decis increas risk relat catalyst time
data pullback valuat investor convinc
compani recent rais capit like need rais
distress valuat without data make rais capit difficult
believ reduct price target warrant
recal decemb soleno announc million pipe led
invest manag schuler birchview capit well
exist investor includ individu entiti affili
compani board director soleno sell share per
share premium approxim last close price share
common get warrant purchas addit share soleno
common stock strike per share year term given
compani last report show cash rais need
term given slno market cap opinion good
focu remain prader-willi syndrom soleno continu
work toward final protocol dccr pw europ
compani receiv posit scientif advic singl pivot trial pw
would support approv import feedback eu regul
agreement feedback fda chang
hyperphagia uncontrol appetite/hung vs placebo primari
endpoint studi trial expect enrol patient
take year complet
safeti data dccr safeti profil consist known profil diazoxid
common treatment-rel advers event also common pw patient includ
sensit measur reduct homa-ir homeostat model assessment-insulin
resist improv
trial design updat data pilot studi dccr
design evalu safeti efficaci multipl dose level dccr patient
age year studi consist open-label treatment phase
dose escal maximum dose patient
improv hyperphagia and/or increas rest energi expenditur
open-label phase classifi respond elig enter
double-blind placebo-control withdraw treatment phase eleven enrol
patient complet open-label phase classifi respond
prader-willi syndrom pw pw complex non-inherit genet condit
aris genom imprint error male femal gametogenesi
meiosi sperm egg format infanc diseas character weak
muscl tone difficulti feed delay develop infant present
abnorm lead physician test pw well-known featur children
pw hyperphagia insati appetit lead chronic over
obes prematur death
diazoxid potassium channel agonist katp approv use
iv treatment malign hypertens use hypoglycemia due
hyperinsulin infant children adult
click full note
lower price definit proof
concept poc take time money
increas therapeut rate cut model
take price target still substanti higher versu
current stock price due combin factor includ
trial delay biomark take time money
compani capit today believ lot capit
need next phase clinic develop get underway
see meaning clinic data convinc kol
industri expert compani may drug take time
recal anavex recent report decemb quarter fye-sept
oper expens end period cash
current burn rate anavex runway multipl
catalyst initi trial alzheim diseas ad rett syndrom
parkinson diseas pd
valuat pull back view follow conclus
trial ad expect studi would initi later
howev would without incorpor new genom
biomark data respond enrich trial manag made
strateg decis evalu full genom sequenc patient
design better program thu trial expect start
conclus anavex smart trial design capit runway
next set catalyst necessarili definit proof concept
data result increas risk cut therapeut model
lower price target one
valu new treatment alzheim diseas central nervou system
note area high difficulti drug develop high
failur rate math-bas model account well predict clinic
outcom result comfort conserv
identifi respond genom sequencing- technolog mine
biomark data enrich trial patient like respond therapi continu
evolv becom embed clinic trial process seen
oncolog space studi mild-moder alzheim diseas
ad patient treat oral daili dose
drug well toler demonstr stabil cognit
function measur baselin one year maintain patient
evalu month mmse mini-ment state exam adcs-adl- alzheim
diseas activ daili inventori eeg/erp- electroencephalographi event-
relat potenti given demonstr dose respons anavex use deep
sequenc whole genom patient studi identifi biomark gene
signatur respond non-respond use enrich upcom trial
rational right patient studi risk go
chanc posit outcom increas anavex also use biomark
indic
click full note
travers data trough lower price
see catalyst year ahead
remain posit hope posit outcom athersi
stroke trial underway predict outcom howev difficult one
near term concern data expect see result either
treasur japan trial trial best
result need travers data trough
cash balanc sheet provid
year worth oper capit view hope athersi
may partner licens multistem increas work capit
versu rais capit market prior data
risk valuat adjust model sever place
result lower year price target current
valuat metric includ therapeut risk cut stroke model
success stroke becom transform compani howev risk
failur indic quit high model feed
incom statement appli discount rate
fcff dep part model arriv fair valu target
per share caution investor math-bas metric lack
predict valuat especi period time lack
data pivot event outcom two stroke trial one
japan one us/europ catalyst year ahead could includ
partnership activ data outsid stroke well competitor success
regen space could caus sector valuat appreci
given current depress valuat believ reduc price target
discuss prudent
global stroke effort europe/fda japan decis consist
messag cell therapi safe burden trial focus
efficaci demonstr signific p-valu around primari endpoint us/
europ trial design almost ident japan except primari endpoint
us trial shift analysi secondari endpoint excel
outcom japan trial opposit
primari endpoint us/europ differ p-valu modifi rankin scale
mr shift analysi metric consid disabl across full spectrum
enabl recognit larg small improv disabl differ
mortal seriou outcom among stroke differ sever
base disabl use mr three month paramet consist
japan us trial treatment window hour
key secondari endpoint primari endpoint japan trial excel
outcom score mr nihss barthel index three month
one year addit studi consid measur function recoveri
biomark data clinic outcom includ hospit mortal life
threaten advers event post-strok complic infect
administr window within hour stroke maxim
impact limit window hour note access window reach
stroke patient
click full note
right valuat cytori binari event
ahead lower price
cytori face fda decis near term habeo move forward
fda could approv habeo base exist data set
combin revis approv pathway centuri cure act
fda could request modest redo exist clinic data set
fda could request new pivot program start scratch
fda decis like impact valuat start scratch scenario
mean addit time money like pressur valuat
advis caution cytori small capit biotechnolog compani
limit resourc high risk predict action regulatori bodi
clinic data outcom difficult cytori consid
aggress investor awar risk present suggest investor
review price invest risk section end note
addit check compani file comprehens list
risk present
valuat risk adjust model slightli valuat
paramet alreadi use discount rate normal
stick well establish compani emerg growth
compani earli stage compani revenu still rais
capit howev reduc margin assumpt result
price target fall back caution investor howev
tri model outcom realiti good clinic
data mean valuat rise poor clinic data mean fall market
opportun cytori substanti scleroderma raynaud syndrom
repres unmet medic need predict approv difficult quantifi
resourc cash alway concern
habeo believ habeo repres uniqu combin safeti
safe therapi essenti uniqu pathway devic
combin chang global regulatori landscap centuri
cure act similar revis europ japan could result approv without
new trial small bridg studi
habeo approv stand today believ habeo new
trial base exist data set decent chanc approv fact
believ either approv approv post market requir
small addit studi like outcom
know soon manag plan meet regul
understand option year end believ centuri
cure act expedit access program eap habeo qualifi
data realli support approv examin data present
compani latest slide deck specif exhibit suggest real effect
data primari secondari endpoint statist signific week
effect seen diffus sever patient pronounc ae rate
higher placebo group safeti profil basic perfect
trial run placebo activ control placebo rate
higher expect salin canal truli placebo would argu
control posit effect break scar tissu induc
heal bestow therapeut benefit
click full note
maxim analyst coverag univers
